P00533 (EGFR_HUMAN) Homo sapiens (Human)

Epidermal growth factor receptor UniProtKBInterProSTRINGInteractive Modelling

1210 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4)

Available Structures

267 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
The Extracellular and Transmembrane Domain Interfaces in Epidermal Growth Factor Receptor Signaling Heteromer
P01133;
25-638
12×NAG;2PE;
Assess
Nanobody EgB4 bound to the full extracellular EGFR-EGF complex Heteromer
P01133;
25-638
14×NAG;
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. "tips-jux… Heteromer
P01133;
25-638
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha "tips-sepa… Heteromer
P01135;
25-638
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF. "tips-separated… Heteromer
P01133;
25-638
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF "tips-juxtaposed… Heteromer
P01133;
25-638
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. "tips-sep… Heteromer
P01133;
25-638
Assess
Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha. "tips-jux… Heteromer
P01135;
25-638
Assess
The complex structure of extracellular domain of EGFR and GC1118A Heteromer
25-637
NAG;NAG;NAG;
Assess
Structure of the extracellular domain of the epidermal growth factor receptor in complex with the F… Heteromer
26-638
NAG;NAG;NAG;
Assess
Crystal structure of the extracellular domain of the epidermal growth factor receptor in complex wi… Heteromer
26-638
NAG;NAG;NAG;NAG;
Assess
Structure of the extracellular domain of human epidermal growth factor (EGF) receptor in an inactiv… Heteromer
P01133;
27-638
NAG;NAG;NAG;
Assess
The complex structure of extracellular domain of EGFR with Repebody (rAC1). Heteromer
E0ACT6; Q4G1L3;
26-637
NAG;NAG;
Assess
Crystal structure of the complex of 059-152-Fv and EGFR-ECD Heteromer
28-638
NAG;NAG; 20×ZN;
Assess
Nanobody/VHH domain 9G8 in complex with the extracellular region of EGFR Heteromer
28-636
NAG;NAG;
Assess
Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain Heteromer
P0DOX5; Q8TCD0;
28-636
NAG;NAG;NAG;
Assess
Nanobody/VHH domain EgA1 in complex with the extracellular region of EGFR Heteromer
28-628
NAG;NAG;
Assess
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domain… Heteromer
P01133;
26-536
NAG;NAG;
Assess
Crystal Structure of Human Epidermal Growth Factor Receptor (residues 1-501) in complex with TGF-al… Heteromer
P01135;
25-525
NAG;NAG;NAG;NAG;PT; 11×CD;CL;NAG;
Assess
Crystal structure of the epidermal growth factor receptor extracellular region in complex with epir… Heteromer
O14944;
26-525
NAG;NAG;NAG;
Assess
Crystal structure of the epidermal growth factor receptor extracellular region with A265V mutation … Heteromer
O14944;
26-525
NAG;NAG;
Assess
Crystal structure of the epidermal growth factor receptor extracellular region with R84K mutation i… Heteromer
O14944;
27-525
NAG;NAG;NAG;
Assess
Crystal structure of the epidermal growth factor receptor extracellular region in complex with epig… Heteromer
Q6UW88;
27-525
NAG;NAG;
Assess
Crystal structure of the epidermal growth factor receptor extracellular region with R84K mutation i… Heteromer
O14944;
27-525
NAG;NAG;MAN;BMA;
Assess
Crystal structure of the extracellular region of the epidermal growth factor receptor in complex wi… Heteromer
Q6GMX6;
263-637
NAG;NAG;NAG;
Assess
EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE Heteromer
P29353;
696-1018
Assess
Crystal structures of EGFR in complex with Mig6 Heteromer
Q9UJM3;
696-1018
Assess
Crystal structures of EGFR in complex with Mig6 Heteromer
Q9UJM3;
696-1018
Assess
Crystal structure of L858R + T790M EGFR kinase domain in complex with MIG6 peptide Heteromer
Q9UJM3;
703-1019
Assess
Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide Heteromer
Q9UJM3;
703-1018
SO4;
Assess
Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide Heteromer
Q9UJM3;
702-1002
Assess
Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-E… Heteromer
P21860;
688-984
ANP;MG;ADP;
Assess
Crystal structure of an EGFR/HER3 kinase domain heterodimer Heteromer
P21860;
688-984
ANP;MG;ADP;
Assess
Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-Q… Heteromer
P21860;
688-984
ANP;MG;ADP;
Assess
Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide Heteromer
Q9UJM3;
699-983
Assess
crystal structure of EGFR kinase domain in complex with Mitogen-inducible gene 6 protein Heteromer
Q9UJM3;
703-985
Assess
Nanobody/VHH domain 7D12 in complex with domain III of the extracellular region of EGFR, pH 6.0 Heteromer
335-535
NAG;MES;NAG;IOD;
Assess
anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region Heteromer
334-527
NAG;NAG;GOL;
Assess
Nanobody/VHH domain 7D12 in complex with domain III of the extracellular region of EGFR, pH 3.5 Heteromer
335-527
NAG;NAG;
Assess
Crystal structure of isolated domain III of the extracellular region of the epidermal growth factor… Heteromer
Q6GMX6;
335-526
NAG;NAG;NAG;SO4;
Assess
Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3 mutant S… Heteromer
335-525
SO4;GOL;EDO;1PE;
Assess
Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3. Heteromer
336-525
SO4;GOL;1PE;
Assess
Crystal structure of the Fab fragment of necitumumab (Fab11F8) in complex with domain III from a ce… Heteromer
335-524
NAG;NAG;NAG;
Assess
Crystal structure the Fab fragment of matuzumab (Fab72000) in complex with domain III of the extrac… Heteromer
336-524
NAG;BMA;
Assess
Heterodimeric association of Transmembrane domains of ErbB1 and ErbB2 receptors Enabling Kinase Act… Heteromer
P04626;
634-677
Assess
Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR Heteromer
311-326
Assess
Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR Heteromer
311-326
ACT;GOL;FMT;
Assess
Crystal structure of c-Cbl TKB domain in complex with double phosphorylated EGFR peptide Heteromer
P22681;
1064-1074
Assess
Crystal structure of c-Cbl-TKB domain complexed with its binding motif in EGF receptor Heteromer
P22681;
1064-1074
Assess
Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 peptide Heteromer
Q13191;
1066-1075
NA;CL;SO4;EDO;
Assess
Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR pY1069 peptide Heteromer
Q9ULV8;
1066-1075
NA;NI;
Assess
Crystal structure of the tyrosine kinase binding domain of Cbl-c in complex with phospho-EGFR pepti… Heteromer
Q9ULV8;
1067-1074
CA;
Assess
Crystal structure of the tyrosine kinase binding domain of Cbl-c (PL mutant) in complex with phosph… Heteromer
Q9ULV8;
1067-1074
CA;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with LXX-6-26homo-4-mer700-1016
816;EDO;
Assess
Crystal structure of the EGF receptor juxtamembrane and kinase domainshomo-2-mer676-1018
Assess
Crystal structure of mutated EGFR kinase domain (G719S)homo-2-mer696-1019
Assess
Crystal structure of EGFR double mutant (T790M/L858R) in complex with compound 6.homo-2-mer696-1019
35Z;
Assess
Crystal Structure of the active EGFR kinase domain in complex with an ATP analog-peptide conjugatehomo-2-mer696-1019
CL;112;
Assess
Crystal structure of EGFR kinase domain in complex with compound 3ghomo-2-mer696-1019
KJR;
Assess
Crystal structure of EGFR kinase domain in complex with compound 2ahomo-2-mer696-1019
KJQ;
Assess
Crystal structure of EGFR kinase domain in complex with compound 4chomo-2-mer696-1019
KJV;
Assess
Crystal structure of EGFR kinase domain in complex with compound 4bhomo-2-mer696-1019
KJ8;
Assess
Crystal structure of EGFR 696-1022 T790M/C797S in complex with Go6976homo-2-mer697-1020
85X;CL;
Assess
Crystal structure of the wild-type EGFR kinase domain in complex with AMPPNP.homo-2-mer696-1018
ANP;
Assess
Crystal Structure of the active EGFR kinase domainhomo-2-mer696-1018
Assess
Crystal structure of mutated EGFR kinase domain (L858R) in complex with AMPPNPhomo-2-mer696-1018
ANP;
Assess
EGFR in complex with a dihydrodibenzodiazepinone allosteric inhibitor.homo-2-mer698-1019
ANP;O57;MG;AMP;EDO;
Assess
Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with AMPPNP.homo-2-mer697-1018
ANP;
Assess
Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with gefitinibhomo-2-mer697-1018
IRE;MES;
Assess
Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in the apo formhomo-2-mer697-1018
MES;
Assess
EGFR L858R/T790M in complex with PD168393homo-2-mer697-1017
YUN;
Assess
Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(6)homo-2-mer697-1014
7XU;
Assess
Crystal structure of EGFR 696-1022 T790M/V948R, crystal form IIhomo-2-mer699-1015
ANP;MG;
Assess
EGFR kinase domain in complex with mutant selective allosteric inhibitorhomo-2-mer698-1014
MG;ANP;57N;
Assess
Crystal structure of EGFR(T790M/V948R) in complex with LN3753homo-2-mer699-1014
TOV;CL;
Assess
Crystal Structure of the inactive EGFR kinase domain in complex with AMP-PNPhomo-2-mer701-1016
MG; 11×IOD;ANP;
Assess
Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(3)homo-2-mer700-1014
CL;EDO;7XO;ANP;MG;
Assess
EGFR(T790M/V948R) in complex with LN2057homo-2-mer700-1014
CL;QQJ;
Assess
EGFR(T790M/V948R) in complex with LN2899homo-2-mer701-1014
CL;EDO;QP1;
Assess
EGFR(T790M/V948R) in complex with LN2380homo-2-mer701-1014
CL;QQM;
Assess
EGFR(T790M/V948R) in complex with LN2725homo-2-mer701-1014
QP4;CL;
Assess
A crystal structure of EGFR(T790M/V948R) in complex with LN3754homo-2-mer701-1014
ANP;MG;
Assess
Crystal structure of EGFR with mutant-selective dihydrodibenzodiazepinone allosteric inhibitorhomo-2-mer701-1013
ANP;NQ1;MG;
Assess
EGFR with an allosteric inhibitorhomo-2-mer699-1007
MG;ANP;JBJ;
Assess
Crystal structure of the inactive EGFR kinase domain in complex with AMP-PNPhomo-2-mer699-1007
ANP;MG;
Assess
EGFR kinase (T790M/V948R) in complex with allosteric inhibitor JBJ-09-063homo-2-mer700-1007
MG;ANP;VNS;
Assess
EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-04-125-02homo-2-mer700-1007
ANP;MG;JBJ;
Assess
EGFR kinase (T790M/V948R) in complex with osimertinib and EAI045homo-2-mer700-1007
ANP;MG;9LL;
Assess
EGFR kinase (T790M/V948R) in complex with AZ5104homo-2-mer700-1007
VO7;
Assess
EGFR(T790M/V948R) in complex with LN2084homo-2-mer701-1008
QP7;CL;
Assess
EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-09-063homo-2-mer700-1007
YY3;VNS;
Assess
EGFR L858R/V948R in complex with osimertinib and allosteric inhibitor JBJ-09-063homo-2-mer701-1008
VNS;YY3;
Assess
EGFR kinase (T790M/V948R) in complex with PF-06747775homo-2-mer700-1007
8BS;
Assess
EGFR kinase (T790M/V948R) in complex with PF-06747775 and JBJ-04-125-02homo-2-mer700-1007
ANP;MG;JBJ;8BS;
Assess
EGFR kinase (L858R/V948R) in complex with allosteric inhibitor JBJ-09-063homo-2-mer700-1007
MG;ANP;VNS;
Assess
Crystal structure of EGFR in complex with EAI045homo-2-mer701-1007
MG;ANP;9LL;
Assess
EGFR transmembrane - juxtamembrane (TM-JM) segment in bicelles: MD guided NMR refined structure.homo-2-mer642-697
Assess
Homodimeric transmembrane domain of the human receptor tyrosine kinase ErbB1 (EGFR, HER1) in micell…homo-2-mer634-677
Assess
N-terminal motif dimerization of EGFR transmembrane domain in bicellar environmenthomo-2-mer634-677
Assess
Crystal structure of EGFR 696-1022 T790M in complex with QL-X138monomer694-1021
3LH;
Assess
Crystal structure of apo EGFR kinase domainmonomer695-1020
MES;SO4;
Assess
1.85 angstrom structure of EGFR kinase domain with gefitinibmonomer696-1020
IRE;NA;MES;
Assess
EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1amonomer696-1020
6HJ;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with AZD9291monomer696-1020
YY3;
Assess
Tyrosine Kinase Domain from Epidermal Growth Factor Receptormonomer696-1020
Assess
EGFR-K IN COMPLEX WITH N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-phenyl] Pro…monomer696-1020
1WY;NA;
Assess
Crystal Structure of EGFR 696-1022 T790M Mutant Covalently Binding to WZ4002monomer696-1020
0UN;
Assess
Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jabmonomer696-1020
DJK;
Assess
Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 13-jabmonomer696-1020
CL;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with WZ4003monomer696-1020
0UN;
Assess
1.9 angstrom structure of EGFR kinase domainmonomer696-1019
NA;MES;
Assess
EGFR kinase domain mutant "TMLR" with compound 41amonomer696-1019
SO4;4ZQ;
Assess
Wild type EGFR in complex with LN2057monomer696-1019
QQJ;
Assess
EGFR kinase domain mutant "TMLR" with compound 23monomer696-1019
SO4;4YX;
Assess
EGFR kinase domain mutant "TMLR" with 3-carboxamide azaindole compound 13monomer696-1019
SO4;60D;
Assess
Crystal structure of EGFR kinase domain L858R mutation in complex with AMP-PNPmonomer696-1019
ANP;
Assess
Crystal structure of EGFR kinase domain G719S mutation in complex with AMP-PNPmonomer696-1019
MG;ANP;
Assess
Crystal Structure of EGFR-WT in Complex with TAK-788monomer697-1020
R28;MES;
Assess
Crystal structure of the EGFR kinase domain in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl…monomer695-1018
8BM;
Assess
Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitormonomer696-1019
FZP;
Assess
Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotin…monomer696-1019
AQ4;
Assess
EGFR kinase domain mutant "TMLR" with 3-azetidinyl azaindazole compound 21monomer696-1019
SO4;60E;
Assess
Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Seriesmonomer695-1018
6GY;
Assess
EGFR kinase domain with compound 41amonomer697-1020
4ZQ;
Assess
EGFR-KINASE IN COMPLEX WITH COMPOUND 5monomer696-1019
L1K;DMS;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with XTF-262monomer696-1019
F62;
Assess
Crystal structure of EGFR kinase domain L858R mutation in complex with Iressamonomer697-1020
CL;IRE;
Assess
Wild type EGFR in complex with LN2380monomer696-1019
QQM;
Assess
Crystal structure of the wild-type EGFR kinase domain in complex with dacomitinib (soaked)monomer695-1018
1C9;
Assess
EGFR kinase domain mutant "TMLR" with compound 27monomer696-1019
SO4;4ZB;
Assess
Crystal structure of EGFR kinase domain L858R mutation in complex with AFN941monomer696-1019
ITQ;
Assess
EGFR kinase domain mutant "TMLR" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-m…monomer696-1019
SO4;5Q4;
Assess
Crystal structure of EGFR kinase domain in complex with compound 78monomer696-1019
CKO;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with SKLB(3)monomer697-1020
7XO;CL;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with SKLB(5)monomer697-1020
7XR;CL;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with SKLB(6)monomer697-1020
7XU;CL;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with Go6976monomer696-1019
85X;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with JTS-1-39monomer697-1020
81C;EDO;CL;
Assess
Crystal structure of EGFR kinase domain in complex with AEE788monomer697-1020
AEE;
Assess
Crystal Structure of EGFR T790M mutant in complex with naquotinibmonomer697-1020
8RC;
Assess
Crystal structure of EGFR kinase domain G719S mutation in complex with Iressamonomer696-1019
IRE;
Assess
Wild type EGFR in complex with LN2899monomer696-1019
QP1;
Assess
Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinibmonomer696-1018
YY3;
Assess
EGFR kinase domain mutant "TMLR" with compound 41bmonomer696-1018
SO4;4ZR;
Assess
Crystal Structure of EGFR(L858R/T790M/C797S) in complex with CH7233163monomer696-1018
EUX;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with CO-1686monomer696-1018
8JC;
Assess
EGFR kinase domain mutant "TMLR" with compound 30monomer697-1019
SO4;4ZH;
Assess
The crystal structure of EGFR T790M/C797S with the inhibitor HC5476monomer696-1018
I0A;
Assess
EGFR L858R in complex with PD168393monomer697-1019
DJK;CL;
Assess
The crystal structure of EGFR T790M/C797S with the inhibitor HCD2892monomer696-1018
7VH;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by soakingmonomer696-1018
YY3;
Assess
EGFR kinase domain mutant "TMLR" with azabenzimidazole compound 7monomer696-1018
SO4;60B;
Assess
EGFR kinase domain mutant "TMLR" with compound 29monomer697-1019
4ZG;
Assess
EGFR kinase domain mutant "TMLR" with a imidazopyridinyl-aminopyrimidine inhibitormonomer697-1019
SO4;63N;
Assess
EGFR kinase domain mutant "TMLR" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{N}-[4…monomer697-1019
5Q2;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with CO-1686monomer696-1018
8JC;
Assess
Crystal structure of EGFR kinase domain L858R mutation in complex with AEE788monomer697-1019
AEE;
Assess
EGFR kinase domain mutant "TMLR" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{N}-…monomer697-1019
SO4;5Q3;
Assess
The structure of co-crystals of 8r-B-EGFR WT complexmonomer696-1018
C6O;
Assess
EGFR kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin…monomer696-1018
5Q4;
Assess
EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATEmonomer696-1018
Assess
EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1bmonomer697-1019
6HL;
Assess
EGFR kinase domain mutant "TMLR" with a pyrazolopyrimidine inhibitormonomer696-1018
63M;
Assess
Crystal structure of EGFR kinase domain in complex with AFN941monomer696-1018
ITQ;
Assess
EGFR kinase domain mutant "TMLR" with compound 17monomer697-1019
4YW;
Assess
The structure of co-crystals of 8r-B-EGFR T790M/C797S complexmonomer696-1018
C6O;
Assess
Crystal structure of EGFR kinase domain in complex with AMP-PNPmonomer697-1019
ANP;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 5monomer697-1019
3QY;
Assess
Native-SAD phasing for human EGFR kinase domain.monomer697-1019
Assess
EGFR-KINASE IN COMPLEX WITH COMPOUND 1monomer697-1019
L1H;
Assess
Crystal structure of EGFR kinase domain in complex with Iressamonomer697-1019
IRE;
Assess
EGFR T790M/C797S in complex with compound 6imonomer696-1017
9JO;
Assess
Active conformation of EGFR kinase in complex with BI-4020monomer696-1017
CL;XA4;
Assess
EGFR kinase domain mutant "TMLR" with compound 33monomer697-1018
SO4;4ZJ;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 8monomer697-1018
SO4;3QS;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 1monomer697-1018
SO4;3R1;
Assess
Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19hmonomer697-1018
MES;L0N;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 27: ~{N}-(1~{H}-indazol-3-yl)-7,7-dimethyl-2-(2-m…monomer697-1018
5N4;
Assess
Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Seriesmonomer697-1018
R85;
Assess
Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40monomer697-1018
JAU;
Assess
EGFR-KINASE IN COMPLEX WITH COMPOUND 6monomer696-1017
L3Z;DMS;
Assess
Crystal structure of EGFR kinase domain G719S mutation in complex with AFN941monomer697-1018
ITQ;
Assess
EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.monomer697-1018
5X4;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 4monomer697-1018
SO4;3R0;
Assess
EGFR kinase domain mutant "TMLR" with compound 24monomer697-1018
4Z8;
Assess
Crystal structure of EGFR kinase domain G719S mutation in complex with AEE788monomer697-1018
AEE;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 6monomer697-1018
3QW;
Assess
EGFR kinase (T790M/L858R) with inhibitor compound 15: ~{N}-(7-chloranyl-1~{H}-indazol-3-yl)-7,7-dim…monomer697-1018
5N3;
Assess
EGFR kinase (T790M/L858R) apomonomer697-1018
Assess
EGFR kinase domain mutant "TMLR" with compound 1monomer697-1018
4YV;
Assess
Crystal structure of EGFR 696-1022 L858R in complex with FIIN-3monomer697-1018
FI3;
Assess
EGFR kinase domain (L858R/V948R) in complex with 2-[4-(difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-…monomer701-1021
EDO;MES;KXY;
Assess
EGFR Kinase domain T790M/L858R mutant with compound 2monomer698-1018
W2P;
Assess
Crystal structure of EGFR 696-1022 T790M/C797S in complex with D3003monomer697-1017
9JO;CL;
Assess
EGFR kinase domain in complex with a covalent aminobenzimidazole inhibitor.monomer697-1017
5X4;
Assess
Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19gmonomer697-1017
L0Q;MES;
Assess
Crystal structure of EGFR kinase in complex with BIBW2992monomer696-1016
0WN;0WM;
Assess
Crystal structure of EGFR kinase domain T790M mutation in complex with AEE788monomer696-1016
AEE;
Assess
Crystal structure of EGFR kinase domain T790M mutationmonomer696-1016
Assess
Crystal structure of EGFR kinase T790M in complex with BIBW2992monomer696-1016
0WN;
Assess
EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLEmonomer697-1017
5XH;
Assess
EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(h…monomer700-1019
KY9;SO4;
Assess
EGFR Kinase domain T790M/L858R mutant with compound 4monomer698-1017
W2R;EDO;
Assess
EGFR kinase domain T790M/L858R mutant with HKI-272monomer698-1017
HKI;MES;
Assess
EGFR Kinase domain T790M/L858R Mutant with TAK-285monomer698-1017
03P;
Assess
AZD9291 complex with wild type EGFRmonomer698-1017
YY3;
Assess
EGFR kinase domain mutant (T790M/L858R) with covalent ligand NS-062monomer698-1017
8LU;
Assess
EGFR kinase domain with compound4monomer701-1019
W2R;SO4;
Assess
EGFR kinase domain complexed with compound 19bmonomer701-1018
W19;SO4;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with Ibrutinibmonomer700-1017
1E8;
Assess
EGFR Kinase domain complexed with tak-285monomer701-1017
SO4;03P;
Assess
EGFR kinase domain complexed with compound 20amonomer701-1017
W32;SO4;
Assess
EGFR kinase domain complexed with a quinazoline inhibitor- GW572016monomer702-1018
PO4;FMM;
Assess
Crystal structure of the EGFR kinase domain mutant V924Rmonomer700-1015
ANP;MG;
Assess
Crystal structure of the EGFR kinase domain mutant I682Qmonomer699-1014
ANP;MG;
Assess
Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(5)monomer700-1015
EDO;7XR;
Assess
Structure of the monomeric (V948R)gefitinib/erlotinib resistant double mutant (L858R+T790M) EGFR ki…monomer700-1014
IRE;SO4;
Assess
Structure of T790M EGFR kinase domain co-crystallized with dacomitinibmonomer700-1014
1C9;
Assess
Structure of EGFR in complex with hydrazone, a potent dual inhibitormonomer702-1016
PO4;HYZ;
Assess
X-ray structure of EGFR in complex with oxime inhibitormonomer702-1015
PO4;POX;
Assess
EGFR(T790M/V948R) in complex with LN3844monomer702-1014
UEJ;
Assess
Crystal Structure of EGFR LRTM with compound 24monomer703-1014
GOL;QFO;
Assess
Crystal structure of the kinase domain of EGFR exon-19 (del-747-749) mutantmonomer698-1009
Assess
Crystal Structure of EGFR LRTM with compound 7monomer703-1011
GOL;QCR;
Assess
EGFR(T790M/V948R) in complex with AZD9291 and DDC4002monomer700-1007
Q6K;NQ1;
Assess
EGFR (T790M/V948R) in complex with quinazolinone allosteric inhibitormonomer700-1007
ANP;MG;YFA;
Assess
Inactive conformation of EGFR (T790M/V948R) kinase in complex with BI-4020monomer700-1007
XA4;
Assess
EGFR (T79M/V948R) in complex with naquotinib and an allosteric inhibitormonomer702-1006
VNS;8RC;
Assess
EGFR D770_N771insNPG in complex with PD168393monomer696-999
YUN;
Assess
EGFR (L858R, T790M, V948R) in complex with N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-py…monomer700-1001
633;SO4;GOL;
Assess
Crystal structure of EGFR tyrosine kinase domain with novel inhibitor of active state of HER2monomer699-999
SO4;6JS;
Assess
EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,…monomer700-999
634;SO4;GOL;
Assess
Crystal structure of EGFR kinase domain in complex with a sulfonyl fluoride probe XO44monomer702-990
O44;SO4;GOL;
Assess
EGFR kinase domain (L858R/V948R) in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[…monomer702-990
KY9;
Assess
Crystal structure of EGFR 696-988 T790M in complex with LXX-6-34monomer697-985
80U; 11×NO3; 19×EDO;CL;
Assess
Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by co-crystallizationmonomer701-989
YY3;CL;
Assess
Crystal structure of EGFR 696-1022 WT in complex with AZD9291 prepared by cocrystallizationmonomer697-984
YY3;CL;
Assess
Crystal structure of the monomeric (V948R) form of the gefitinib/erlotinib resistant EGFR kinase do…monomer701-987
Assess
Crystal structure of monomeric (V948R) primary oncogenic mutant L858R EGFR kinase domainmonomer701-987
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21amonomer700-985
N78;EDO;SO4;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18bmonomer700-985
N7Q;EDO;SO4;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21bmonomer699-984
N82;EDO;SO4;
Assess
EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(h…monomer701-985
EDO;KY9;NO3;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with Spebrutinib and EAI001monomer700-984
57N;7G9;SO4;CL;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with TAK-788monomer700-984
R28;
Assess
Crystal structure of EGFR kinase domain T790M mutation in compex with HKI-272monomer700-984
HKI;
Assess
Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibi…monomer702-985
8AM;SO4;GOL;EDO;
Assess
Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibi…monomer702-985
8BP;SO4;GOL;
Assess
Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibi…monomer702-985
8BS;SO4;GOL;EDO;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18cmonomer699-982
N7Z;SO4;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with Poziotinibmonomer699-982
R2E;SO4;EDO;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with Mavelertinib and EAI001monomer701-984
8BS;SO4;
Assess
EGFR (L858R, T790M, V948R) in complex with 1-[(3R,4R)-3-[({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-p…monomer702-985
63A;SO4;GOL;
Assess
Crystal structure of EGFR 675-1022 T790M/C797S/V948R in complex with EAI045monomer702-985
9LL;
Assess
Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with 4-(4-{[2-{[(3S)-1…monomer703-985
8BM;SO4;GOL;
Assess
EGFR (L858R, T790M, V948R) in complex with 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)…monomer702-984
630;SO4;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18dmonomer700-982
N7W;SO4;MG;CL;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 14dmonomer700-982
N7K;SO4;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with Osimertinib and EAI045monomer700-982
Q6K;9LL;SO4;
Assess
Crystal structure of EGFR kinase domain (L858R, T790M, V948R) in complex with the covalent inhibito…monomer702-984
8OV;
Assess
Structure of EGFR_D770_N771insNPG/V948R in complex with covalent inhibitor Osimertinib.monomer702-984
Q6K;EDO;
Assess
Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 19monomer701-982
N7B;SO4;
Assess
Crystal Structure of EGFR-T790M/V948R in Complex with LDC8201monomer703-984
SO4;R1W;
Assess
Crystal structure of the inactive EGFR tyrosine kinase domain with erlotinibmonomer703-984
AQ4;
Assess
EGFR kinase domain complexed with an imidazo[2,1-b]thiazole inhibitormonomer703-983
ITI;
Assess
A Structural Model for the Membrane-Bound Form of the Juxtamembrane Domain of the Epidermal Growth …monomer669-721
Assess
Spatial structure of EGFR transmembrane and juxtamembrane domains in DPC micellesmonomer642-690
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7syd.1.Cmonomer0.7725-638
99.92
Assess
3bbt.1.Amonomer0.72702-992
FMM;77.85
Assess

6 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23qwq.1.Amonomer0.8226-404
99.75
Assess
Isoform 33qwq.1.Amonomer0.8126-636
98.74
Assess
Isoform 37syd.1.Cmonomer0.8025-631
99.68
Assess
Isoform 31igr.1.Amonomer0.51353-673
26.06
Assess
Isoform 43qwq.1.Amonomer0.8226-627
100.00
Assess
Isoform 47sz0.1.Cmonomer0.8125-627
99.84
Assess